SUBSCRIBE
SUBSCRIBE
News   Drug Development

ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide

February 4, 2008 | 
1 min read
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:
Clinical research Phase 1
MORE ON THIS TOPIC
FDA
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
September 30, 2026
 · 
1 min read
 · 
Jef Akst
Concept idea of light bulb, creative, imagination, motivation, success, and thinking, surreal conceptual art, 3d illustration, painting artwork.
Opinion
Biopharma needs to reward scientists’ judgment
September 30, 2026
 · 
5 min read
 · 
Joanna Ghayad
Businessman walks on the street and sees a question mark.
Huntington’s disease
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
September 29, 2026
 · 
4 min read
 · 
Heather McKenzie
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Obesity
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
September 29, 2026
 · 
2 min read
 · 
Tristan Manalac